158 related articles for article (PubMed ID: 37363972)
1. Updates on the Treatment of Tenosynovial Giant Cell Tumor.
Chan AS; Katiyar V; Dy P; Singh V
Hematol Oncol Stem Cell Ther; 2023 May; 16(4):307-315. PubMed ID: 37363972
[TBL] [Abstract][Full Text] [Related]
2. Treatment updates on tenosynovial giant cell tumor.
Palmerini E; Staals EL
Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
[TBL] [Abstract][Full Text] [Related]
3. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
[TBL] [Abstract][Full Text] [Related]
4. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors.
Baldi GG; Gronchi A; Stacchiotti S
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):571-576. PubMed ID: 32478598
[TBL] [Abstract][Full Text] [Related]
5. Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy.
Palmerini E; Longhi A; Donati DM; Staals EL
Expert Rev Anticancer Ther; 2020 Jun; 20(6):441-445. PubMed ID: 32297819
[TBL] [Abstract][Full Text] [Related]
6. Pexidartinib (TURALIO™): The First FDA-Indicated Systemic Treatment for Tenosynovial Giant Cell Tumor.
Monestime S; Lazaridis D
Drugs R D; 2020 Sep; 20(3):189-195. PubMed ID: 32617868
[TBL] [Abstract][Full Text] [Related]
7. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Brahmi M; Vinceneux A; Cassier PA
Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
[TBL] [Abstract][Full Text] [Related]
8. Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).
Caldwell TM; Ahn YM; Bulfer SL; Leary CB; Hood MM; Lu WP; Vogeti L; Vogeti S; Kaufman MD; Wise SC; Le Bourdonnec B; Smith BD; Flynn DL
Bioorg Med Chem Lett; 2022 Oct; 74():128928. PubMed ID: 35961460
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
[TBL] [Abstract][Full Text] [Related]
10. Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages.
Smith BD; Kaufman MD; Wise SC; Ahn YM; Caldwell TM; Leary CB; Lu WP; Tan G; Vogeti L; Vogeti S; Wilky BA; Davis LE; Sharma M; Ruiz-Soto R; Flynn DL
Mol Cancer Ther; 2021 Nov; 20(11):2098-2109. PubMed ID: 34433663
[TBL] [Abstract][Full Text] [Related]
11. Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.
Robert M; Farese H; Miossec P
Front Immunol; 2022; 13():820046. PubMed ID: 35265077
[TBL] [Abstract][Full Text] [Related]
12. The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.
Bernthal NM; Spierenburg G; Healey JH; Palmerini E; Bauer S; ; Gelderblom H; Staals EL; Lopez-Bastida J; Fronk EM; Ye X; Laeis P; van de Sande MAJ
Orphanet J Rare Dis; 2021 Apr; 16(1):191. PubMed ID: 33926503
[TBL] [Abstract][Full Text] [Related]
13. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
Lingamfelter M; Novaczyk ZB; Cheng EY
JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035
[TBL] [Abstract][Full Text] [Related]
14. Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.
Alsayadi YMMA; Chawla PA
Anticancer Agents Med Chem; 2021; 21(12):1510-1519. PubMed ID: 33143617
[TBL] [Abstract][Full Text] [Related]
15. Role of colony-stimulating factor 1 in the neoplastic process of tenosynovial giant cell tumor.
Tap WD; Healey JH
Tumour Biol; 2022; 44(1):239-248. PubMed ID: 36502356
[TBL] [Abstract][Full Text] [Related]
16. Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor.
Gelderblom H; de Sande MV
Future Oncol; 2020 Oct; 16(29):2345-2356. PubMed ID: 32700568
[TBL] [Abstract][Full Text] [Related]
17. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
Staals EL; Ferrari S; Donati DM; Palmerini E
Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
[TBL] [Abstract][Full Text] [Related]
18. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Tap WD; Gelderblom H; Palmerini E; Desai J; Bauer S; Blay JY; Alcindor T; Ganjoo K; Martín-Broto J; Ryan CW; Thomas DM; Peterfy C; Healey JH; van de Sande M; Gelhorn HL; Shuster DE; Wang Q; Yver A; Hsu HH; Lin PS; Tong-Starksen S; Stacchiotti S; Wagner AJ;
Lancet; 2019 Aug; 394(10197):478-487. PubMed ID: 31229240
[TBL] [Abstract][Full Text] [Related]
19. Multiple systemic treatment options in a patient with malignant tenosynovial giant cell tumour.
Rebuzzi SE; Grassi M; Catalano F; Buscaglia M; Bertulli R; Satragno C; Belgioia L; Comandini D
Anticancer Drugs; 2020 Jan; 31(1):80-84. PubMed ID: 31567307
[TBL] [Abstract][Full Text] [Related]
20. Multimodal management of tenosynovial giant cell tumors (TGCT) in the landscape of new druggable targets.
van der Heijden L; Spierenburg G; Kendal JK; Bernthal NM; van de Sande MAJ
J Surg Oncol; 2023 Sep; 128(3):478-488. PubMed ID: 37537982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
